Concepedia

Thomas Son

TS

6

Publications

485

Citations

6

H-Index

2004

Active since

Affiliations

Acadia Pharmaceuticals (United States)(Current)

MacroGenics (United States)

Thomas Son is an author at Acadia Pharmaceuticals (United States) specializing in drug discovery, molecular pharmacology, and medicine.

ORCID

Top concepts

Publications per year

2004–2022

6

Publications

6

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Kimberly E. Vanover, David M. Weiner, Malath Makhay et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 196 citations · Full text

Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer

Juniper A. Scribner, Jennifer G. Brown, Thomas Son et al. · Molecular Cancer Therapeutics · 2020 · 148 citations

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

Stefania Risso Bradley, Jelveh Lameh, Linda Ohrmund et al. · Neuropharmacology · 2009 · 67 citations

, , +11

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

Kimberly E. Vanover, Scott C. Harvey, Thomas Son et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 27 citations · Full text

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator

Fabrice Piu, Luis R. Gardell, Thomas Son et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2007 · 26 citations

, , +8

Rows per page

1–5 of 6